Home/Syntrix Pharmaceuticals/Dean Y. Maeda, PhD

DY

Dean Y. Maeda, PhD

Director Medicinal Chemistry and Preclinical Development

Syntrix Pharmaceuticals

Therapeutic Areas

Oncology Pain Autoimmunity

Syntrix Pharmaceuticals Pipeline

Drug	Indication	Phase
SX-682	Oncology (Immuno-oncology)	Clinical Development
Desmetramadol	Pain	Clinical Development

Leadership Team at Syntrix Pharmaceuticals

John A. Zebala, MD, PhD

President and CEO

Stuart Kahn, MD

Medical Director

View full Syntrix Pharmaceuticals profile